Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
There is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
The COM has presented on 21.04.2022 a new ppt regarding the Personnel cost calculation in Horizon Europe.
They have presented a novelty compared to former presentations: the introduction of a double capping (slide 11).
2024-04-16
|
6 days ago |
Update of Horizon Europe Model Grant Agreements (general and unit costs) |
2024-04-10
|
1 week ago |
IGLO report compilation discussion stakeholders on experiences with Horizon Europe Lu... |
2024-02-20
|
2 months ago |
Update of the Certificate on the Financial Statement (CFS) |
2023-10-09
|
6 months ago |
Annual report on implementation of the EU budget for the financial year 2022 by Eur... |
2023-10-09
|
6 months ago |
Last few days to respond to survey: help us further improve NCP Flanders services |
2023-09-27
|
6 months ago |
NCP Flanders survey still open until 13 October |
2023-09-27
|
6 months ago |
Ethics Guidelines for Trustworthy AI - Hints and tips for HEU proposals |
2023-09-08
|
7 months ago |
Agreement reached for the association of the UK to Horizon Europe |
We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.